{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:54:09Z","timestamp":1780635249921,"version":"3.54.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Previous prostate stereotactic body radiation therapy studies delivered uniform doses of 35 to 40\u2009Gy\/5 fx. Attempts at uniform dose escalation to 50\u2009Gy caused high rates of gastrointestinal (GI) toxicity. We hypothesize that heterogeneous dose escalation to regions nonadjacent to sensitive structures (urethra, rectum, and bladder) is safe and efficacious.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Patients were enrolled on a prospective pilot study. The primary endpoint was treatment-related GI and genitourinary (GU) toxicity. The secondary endpoints included quality of life (QOL) assessed by the EPIC-26 questionnaire and biochemical control. The target volume received 36.25\u2009Gy\/5 fx. The target &gt;3\u2009mm from sensitive was dose escalated to 50\u2009Gy\/5 fx.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-five patients were enrolled. Three patients had low, 14 intermediate, and 18 high-risk disease. The mean initial prostate specific antigen was 15.1\u2009ng\/mL. Androgen deprivation therapy was given to 19 patients. Median follow-up was 46 months. Urinary irritation\/obstructive and urinary bother scores declined by minimal clinically important difference threshold from baseline at 6 weeks, but subsequently recovered by 4 months. No differences in QOL scores were observed for urinary incontinence, bowel domain, bloody stools, or sexual domain. One patient developed acute grade 4 GU toxicity and acute grade 4 GI toxicity. The incidence of late high grade toxicity was 1\/35 for GU toxicity and 2\/35 for GI toxicity. Freedom from biochemical failure at 3 years was 88.0%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Heterogeneous dose-escalated prostate stereotactic body radiation therapy is feasible with low rates of acute and late toxicities and favorable QOL outcomes in patients with predominantly intermediate-risk and high-risk prostate cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000693","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T20:58:09Z","timestamp":1588193889000},"page":"469-476","source":"Crossref","is-referenced-by-count":6,"title":["Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer"],"prefix":"10.1097","volume":"43","author":[{"given":"Shireen","family":"Parsai","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Sedor","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana A.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Thousand","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Magnelli","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Berglund","sequence":"additional","affiliation":[{"name":"Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stovsky","sequence":"additional","affiliation":[{"name":"Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul D.","family":"Tendulkar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Stephans","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown university experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (sharp), 33.5 Gy in five fractions for localized disease: first clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2490-10-1","article-title":"Stereotactic body radiotherapy for organ-confined prostate cancer","volume":"10","author":"Katz","year":"2010","journal-title":"BMC Urol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fonc.2016.00168","article-title":"Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: risk-stratification and patterns of failure","volume":"6","author":"Katz","year":"2016","journal-title":"Front Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"2420786","DOI":"10.1155\/2016\/2420786","article-title":"Evolving paradigm of radiotherapy for high-risk prostate cancer: current consensus and continuing controversies","volume":"2016","author":"Juloori","year":"2016","journal-title":"Prostate Cancer"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase I dose escalation study using stereotactic body radiosurgery for patients with low and intermediate risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fonc.2014.00319","article-title":"Stereotactic body radiation therapy for prostate cancer: review of experience of a multicenter phase I\/II dose-escalation study","volume":"4","author":"Kim","year":"2014","journal-title":"Front Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1464-410X.2011.10861.x","article-title":"Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer","volume":"110","author":"Berglund","year":"2012","journal-title":"BJU Int"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","article-title":"Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy","volume":"92","author":"Mariados","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.12.019","article-title":"A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes","volume":"87","author":"Song","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/MD.0000000000000290","article-title":"Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"New Engl J Med"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijrobp.2016.12.014","article-title":"A comparison between low-dose-rate brachytherapy with or without androgen deprivation, external beam radiation therapy with or without androgen deprivation, and radical prostatectomy with or without adjuvant or salvage radiation therapy for high-risk prostate cancer","volume":"97","author":"Ciezki","year":"2017","journal-title":"Int J Radiati Oncol Biol Phys"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase I\/II study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncology"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation","volume":"104","author":"Alayed","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1748-717X-7-82","article-title":"Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy","volume":"7","author":"Vainshtein","year":"2012","journal-title":"Radiat Oncol"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2019.01.092","article-title":"Outcomes of a dose-escalated stereotactic body radiation phase 1 trial for patients with low- and intermediate-risk prostate cancer","volume":"104","author":"Potters","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:03:59Z","timestamp":1693713839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000693"}},"subtitle":["Quality of Life and Clinical Outcomes of an Institutional Pilot Study"],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000693","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}